A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding After Administration of TX-12-002-HR in Estrogen-Primed Women With Secondary Amenorrhoea

Trial Profile

A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding After Administration of TX-12-002-HR in Estrogen-Primed Women With Secondary Amenorrhoea

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Progesterone (Primary)
  • Indications Amenorrhoea
  • Focus Registrational; Therapeutic Use
  • Acronyms SPRY
  • Sponsors TherapeuticsMD
  • Most Recent Events

    • 24 Nov 2014 Last checked against ClinicalTrials.gov record.
    • 19 Nov 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 04 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top